Pharmacology, physiology, and mechanisms of incretin hormone action.

By Jonathan E. Campbell, D. J. Drucker. Cell Metabolism, 2013

1,381 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/bd159cc785b25fb478a3bc0dd1fd2b1784c89a73

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. G. Svegliati-Baroni
2. D. J. Drucker
3. F. Marra

In Molecular Biology

1. G. Svegliati-Baroni
2. D. J. Drucker
3. F. Marra

In Surgery

1. G. Svegliati-Baroni
2. D. J. Drucker
3. F. Marra

Citations in the corpus

• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024, background): “34,39,177 The rise in cAMP activates protein kinase A (PKA), which then promotes the synthesis and secretion of insulin and inhibits the release of glucagon.”
• Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. (2018, methodology): “GLP-1R agonists improve the survival of human islets ex vivo, or following transplantation into animals (Campbell and Drucker, 2013).”
• Lipotoxicity and the gut-liver axis in NASH pathogenesis. (2018, background): “effective in stimulating the pancreatic secretion of insulin and in inhibiting glucagon release, but are resistant to the proteolytic action of dipeptidyl peptidase-4, which degrades GLP-1 within a few minutes in vivo [115, 117].”